The 2014 Alzheimer’s Association report finds that women bear the brunt of AD, being more likely to develop the disease or care for someone with AD full time.
A Keystone symposium underscores the role of lysosomal dysfunction and vesicle trafficking in neurodegenerative disease.
Keystone Symposium: Alzheimer's Disease- From Fundamental Insights to Light at the End of the Translational Tunnel / Parkinson’s Disease: Genetics, Mechanisms and Therapeutics
Combination Trial Debate Energizes Keystone Symposium Protecting Neurons by Ramping Up Waste Disposal? Prodromal Initiative to Identify Biomarkers for Parkinson’s Researchers Build on GWAS to Parse Genetic Players in AD and PD More than 200 researchers ...
Keystone symposium highlights new strategies in the quest to find the biomarkers of Parkinson’s disease.
Keystone presenters pulled out new tools to make connections between genetics and disease.
PINK1 mutations cripple mitochondrial energy production, raising new questions about Parkinson’s disease.
An antioxidant thought to boost mitochondrial function came up short in a large multicenter trial for PD treatment.
Astrocytes kindle neuronal hyperexcitability in mouse models of Huntington’s.
When a calcium sensor disappears from dendritic spines, synapse loss soon follows in Alzheimer’s models, aging mice, and diseased human brains.
The most detailed connectivity map for the mammalian brain to date will allow investigators to track neuronal networks at an unprecedented scale.
A new link between two proteins tied to Parkinson’s has implications for the disease and beyond.
As the adage goes, an ounce of prevention is worth a pound of cure. A new journal aims to find out if this is true for Alzheimer’s.
Older adults with amyloid in their brains develop abnormal activity in the entorhinal cortex even while memory and hippocampal function remain unaffected.
A new bill asks Congress to ramp up Alzheimer’s funding by breaking down the cost to meet each of the milestones in the national plan. It appropriates no funds.
A new bill will centralize the approval process for multinational trials and mandate the publication of trial results—good or bad.